Dana-Farber Cancer Institute

Sorting 28 by

Accepting patients

KT-253

A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-253 in Adult Patients With High Grade Myeloid Malignancies and Acute Lymphocytic Leukemia, Lymphoma and Advanced Solid Tumors
Learn more
  • MDM2 Inhibitor
  • Phase 1

Accepting patients

PROMISE

Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
Learn more
  • High Risk
  • Observational
  • Observational Trial
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials

Accepting patients

ACCESS

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (ACCESS)
Learn more
  • Allogeneic Stem Cell Transplant
  • Pre-Transplant
  • Phase 2

Accepting patients

TakeAim

TakeAim Leukemia: A Phase 1/2A, Open Label Dose Escalation and Expansion Study of Orally Administered CA-4948 as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome and in Combination With Azacitidine or Venetoclax
Learn more
  • BCL-2 Inhibitor
  • Hypomethylating Agents (HMA)
  • IRAK 4 Inhibitor
  • Phase 1/2
  • Has results

Accepting patients

BXCL701

A Phase 1 Study of BXCL701 in Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Myelodysplastic Syndrome With Excess Blasts - 2
Learn more
  • Dipeptidyl Peptidase 4 (DPP-4) Inhibitor
  • Phase 1

Accepting patients

SL-401

Phase 1 Study of SL-401 in Combination With Azacitidine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Treatment-Naive Subjects With AML Not Eligible for Standard Induction and in Subjects With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or SL-401 in Combination With Azacitidine in Subjects With High-Risk Myelodysplastic Syndrome (MDS)
Learn more
  • BCL-2 Inhibitor
  • Hypomethylating Agents (HMA)
  • Phase 1

Accepting patients

AZD6738

A Phase Ib Study of AZD6738 for Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Progressing on Front-Line Therapy
Learn more
  • Kinase Inhibitor
  • Phase 1

Accepting patients

ARC-T Cells Plus SPRX002

Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome, Including Long-term Safety Follow-up
Learn more
  • CAR T Cell
  • Phase 1

Accepting patients

IS-free Treg Stem Cell Transplant

A Pilot/Phase 1 Study of Immunosuppression-free Regulatory T-cell Graft-engineered Haploidentical Hematopoietic Cell Transplantation in Relapsed/Refractory AML/MDS
Learn more
  • Allogeneic Stem Cell Transplant
  • Phase 1

Accepting patients

Venetoclax in Pre- and Post-Transplant Therapy

A Phase 1 Study of Adding Venetoclax to a Reduced Intensity Conditioning Regimen and to Maintenance in Combination With a Hypomethylating Agent After Allogeneic Hematopoietic Cell Transplantation for Patients With High Risk AML, MDS, and MDS/MPN Overlap Syndromes
Learn more
  • Allogeneic Stem Cell Transplant
  • Antimetabolites
  • BCL-2 Inhibitor
  • Chemotherapy
  • Hypomethylating Agents (HMA)
  • Phase 1